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Photochemical internalisation (PCI) is a technique for releasing biologically active macromolecules from endocytic vesicles by light
activation of a photosensitiser localised in the same vesicles of targeted cells. This study investigated the PCI of the toxin gelonin as a
way of enhancing the effect of photodynamic therapy (PDT) on a human malignant fibrous histiocytoma transplanted into nude mice
using the photosensitiser disulphonated aluminium phthalocyanine (AlPcS2a). Pharmacokinetic studies after intraperitoneal
administration showed that the serum level of AlPcS2a fitted a biexponential model (half-lives of 1.8 and 26.7h). The tumour
concentration was roughly constant up to 48h, although fluorescence microscopy showed that the drug location was initially mainly
vascular, but became intracellular by 48h. To compare PDT with PCI, 48h after intraperitoneal injection of 10mgkg
 1 AlPcS2a, and
6h after direct intratumour injection of 50mg gelonin (PCI) or a similar volume of phosphate-buffered saline (PDT controls), tumour-
bearing animals were exposed to red light (150Jcm
 2). Complete response was observed for more than 100 days in 50% of the PCI
tumours but only 10% of the PDT tumours (Po0.01). In tumours examined histologically 4 days after light delivery, the depth of
necrosis was 3–4mm after PDT, but 7mm after PCI. The deeper effect after PCI demonstrates that the light fluence needed to kill
tumour is less than with PDT. We conclude that PCI with gelonin can markedly enhance the effect of PDT on this type of tumour and
may have a role clinically as an adjunct to surgery to control localised disease.
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Photochemical internalisation (PCI) is a new technology, in which
photosensitising drugs are used to improve the utilisation of
macromolecules in cancer therapy in a site-specific manner (Berg
et al, 1999). The concept is to localise the sensitiser and the
macromolecule in endocytic vesicles of target cells and then excite
the photosensitiser with light of an appropriate wavelength
(photodynamic therapy, PDT). This releases the endocytically
located macromolecules into the cytosol, but only in the irradiated
area (PCI). The technique has the advantage of minimal side
effects since the effect is localised to the irradiated area. The
endosomal escape of macromolecules such as transgene substances
can be increased up to a 100-fold or more (Berg et al, 1999; Selbo
et al, 2000). Recently, we have demonstrated a good effect of PCI
on two sarcoma cell lines in vitro (Dietze et al, 2003), although the
available in vivo data is limited (Selbo et al, 2002). The aim of this
study was to determine whether PCI could improve the therapeutic
effect of PDT on a human soft-tissue sarcoma in a mouse model,
particularly to assess whether it might have value as an adjunct to
surgical excision of this type of tumour. Soft-tissue sarcomas are
highly vascularised tumours with a large interstitial space and thus
a low density of tumour cells (Lieberman and Lebovitz, 1990).
These properties may influence the pharmacokinetics of the
photosensitiser as well as the transport and cellular uptake of the
macromolecule of choice.
MATERIALS AND METHODS
Chemicals
Disulphonated aluminium phthalocyanine with the sulphonate
groups on adjacent phthalate rings (AlPcS2a) was provided by
Frontier Scientific (Logan, UT, USA). A stock solution of
2mgml
 1 in phosphate-buffered saline (PBS) was kept at  201C
until use. Gelonin was purified from Gelonium multiflorum by Dr
Gowsala Sivam, Bastyr University, Seattle, USA.
Tumour model
A human malignant fibrous histiocytoma (MFH) xenograft
(TAX1), established in 1988, was provided by Professor Ola
Myklebost, Department of Tumour Biology at the Norwegian
Radium Hospital, Oslo. It was derived from tissue obtained during
resection after local relapse. The tissue was propagated by
implantation of fragments (2mm
3) in the left hind limb of nude
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smice (Balb/c nu/nu). These mice were maintained under specific
pathogen-free conditions, with food and water supplied ad libitum.
Housing and all procedures involving animals were performed
according to protocols approved by the institutional animal care
and use committee, in compliance with the Norwegian Animal
Research Authority’s guidelines on animal welfare and the
guidelines of the UK Co-ordination Committee on Cancer
Research (UKCCCR). To minimise the number of animals
required, not all combinations of values were studied in the
treatment group. Three animals per group were used for the serum
and tissue analysis. The tumour size was measured by caliper in
two dimensions twice a week and the volume calculated by the
formula 0.5 (length width
2). Treatment commenced at a mean
volume of 100mm
3 (s.d.725mm
3). Animals were killed by
cervical dislocation if the volume reached 1000mm
3.
Extraction of the sensitiser from tumour tissue and mouse
serum
Animals injected with 10mgkg
 1 AlPcS2a i.p. were kept in the dark
and 2, 6, 12, 24, 48, 72, 96 and 120h later, intracardiac blood
samples were taken under general anaesthesia terminated by
cervical dislocation. After spinning at 5000r.p.m. for 5min, the
serum was collected and kept frozen until analysed spectro-
scopically as described below to measure the drug concentration.
The entire tumour harvested from the same animal was divided
into two parts, one for chemical extraction of AlPcS2a and one for
fluorescence microscopy. Both parts were immediately frozen in
liquid nitrogen. The tumour tissue used for chemical extraction
was thawed, washed twice in PBS, weighed and then digested in
10ml, 0.1 M NaOH for 4h at 501C. After spinning at 3000r.p.m. for
10min, AlPcS2a was measured spectroscopically in the supernatant
at 672nm (Perkin-Elmer LS-50B spectroscope with an excitation
wavelength of 350nm and emission detected between 550 and
750nm). For calibration, measurements were made on tissues
extracted from animals not given AlPcS2a, but to which known
concentrations of AlPcS2a had been added.
In vivo localization of AlPcS2a
The frozen tissue blocks for localisation of AlPcS2a were mounted
in Tissue Tek II embedding compound (BDH, Poole, UK), and
8mm sections were cut with a cryostat microtome and mounted on
clean glass slides. Fluorescence microscopy was undertaken using
a Nikon Eclipse E800 microscope with a 100W mercury lamp and
fluorescence images were made with a highly light-sensitive
thermo-electrically cooled charge-coupled device (CCD) camera
(Hamamatsu ORCAII-ER, Japan), with a resolution of 1344 1024
pixels and a dynamic range of 16 bits per pixel. The equipment
used a 330–380nm excitation filter, a beam splitter and a 590nm
long-pass emission filter. The same lens ( 20) and integrated
exposure time (2s), known to cause less than 5% photobleaching
of the dye fluorescence, were used throughout the study. The
neighbouring tissue sections were stained with haematoxylin and
eosin (H&E) and transmission images made with a colour CCD
camera (SPOT-RT, Diagnostic Instruments Inc., MI, USA) to
determine the exact microscopic distribution of the dye in the
tumour tissues.
For whole body images, four animals were killed 48h after i.p.
injection of AlPcS2a (10mgkg
 1) and immediately placed in the
light tight chamber of an XFO-6 fluorescence option system
equipped with a CCD camera (IVISt Imaging System 100;
Xenogen Corp. Alameda, CA, USA). The peak AlPcS2a excitation
wavelength was 675nm and emission was measured at 694nm with
a Cy 5.5 filter set, 1s exposure time and a field of vision (FOV) of
25cm
2. Fluorescence emitted from the tumour tissue was used to
generate a false colour image using LivingImage Software
(Xenogen Corp.).
Western blotting
The abundance and stability of gelonin in the tumour tissue after
intratumour (i.t.) injection was investigated by chemical extraction
and Western blotting. Animals received a single i.t. injection of
50mg (25mgkg
 1 b.w.) gelonin dissolved in PBS (pH 7.2) and were
killed 10min, 1, 6, 24 or 48h later. Control animals received no
gelonin. At post mortem, the tumours were excised, snap frozen in
liquid nitrogen and freeze-fractured with a Bio-Pulverizer (BioSpec
Products, Bartlesville, OK, USA) cooled thoroughly with liquid
nitrogen. Then, tissue lysate was prepared by homogenisation in a
modified RIPA buffer (150mM sodium chloride, 50mM Tris-HCl,
pH 7.4, 1mM EDTA, 1mM phenylmethylsulphonyl fluoride, 1%
NP-40, 0.25% Na-deoxycholate, 1mM Na3VO4,1 m M Na-fluoride
and 10mlml
 1 protease inhibitor cocktail (Sigma, Louis, MO,
USA)) for 1h at 41C. Subsequently, tissue and cell debris were
removed by centrifugation and the protein concentration of the
supernatant was determined with a modified Lowry assay (Bio-
Rad, Hercules, CA, USA). The tissue lysates were boiled for 5min
in 1  SDS sample buffer (50mM Tris-HCl pH 6.8, 12.5% glycerol,
1% sodium dodecylsulphate, 0.01% bromophenol blue), separated
by SDS–PAGE (100mg protein well
 1) followed by overnight
transfer to a PVDF membrane (Amersham Biosciences, Buck-
inghamshire, England). The membrane was then blocked in a
TTBS buffer containing 5% dry-milk and afterwards probed for 1h
at room temperature (RT) with a rabbit polyclonal antibody (SIFF,
Oslo, Norway) against gelonin. The membrane was subsequently
washed 3 10min (RT) with TTBS buffer followed by probing
with a HRP-linked goat-anti-rabbit antibody in TTBS buffer
containing 5% dry-milk for 1h at RT. To visualise the specific
bands of gelonin, the ECL Plust (Amersham) Western blotting
detection kit was used. Chemifluorescence was detected by the
Storm
s gel and blot imaging system (Amersham).
Photodynamic therapy and PCI
Tumour-bearing mice were allocated randomly to one of five
groups: 1: PCI, 2: PDT, 3: no treatment, 4: AlPcS2aþgelonin (no
light) and 5: geloninþlight (no AlPcS2a). Groups 1, 2 and 4 were
injected with 10mgkg
 1 i.p. AlPcS2a and kept in the dark for 48h
prior to light delivery (no light in group 4). Injection of 25mlo f
gelonin (2mgkg
 1, groups 1, 4 and 5) or PBS (groups 2 and 3)
directly into the centre of the tumour was performed 6h prior to
delivery of red light from a 150W halogen lamp (Xenophot,
HLX64640) filtered through a 580nm long-pass and a 700nm
short-pass filter (150mWcm
 2, total dose 150Jcm
 2). For light
delivery, the mice were fixed in a holder and the area surrounding
the tumour was completely covered with aluminium foil. The mice
were then kept in subdued light for a further 6 days. Tumour size
was documented twice a week. If there was apparent eradication,
monitoring was reduced to once a week to look for any tumour
recurrence. For histological assessment, separate animals were
killed 4 days after light delivery and the tumours divided at the
centre of the zone of necrosis into two parts in the plane parallel to
the axis of light delivery. The specimens were fixed in 4% formalin
for subsequent sectioning and staining with H&E. All histological
sections were examined microscopically to document the extent of
viable tumour tissue. The first cuts, representing the largest cross-
section in the zone of necrosis were imaged by a scanner and hard
copies printed for further estimation of the areas of viable and
nonviable tumour.
Analysis and statistics
The AlPcS2a serum concentration kinetics was analysed by
nonlinear regression of log concentration vs the log multi-
exponential decay with time. Significant differences between time
points were assessed by one-way analysis of variance. Significant
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sdifferences between PDT and PCI treatment and the histological
findings after the treatment were assessed by t-test analysis.
RESULTS
Serum and tumour pharmacokinetics
Figure 1 shows the variation with time of the AlPcS2a level in the
mouse serum and tumour after i.p. administration. At 2h after
administration, the serum level was relatively high
(B600ngml
 1), but this declined rapidly. The serum clearance
did not follow a simple monoexponential decay, but fitted well to a
biexponential two-compartment model described by the equation
C¼1420e
 0.39tþ41.8e
 0.026t (corr. coeff. R¼0.9916). The model
gives two half-lives of 1.870.58 and 26.772.9h, correlating to
elimination rate constants of 0.3970.13 and 0.02670.003h
 1.A
three-compartment model did not improve the correlation with
the observations.
One-way analysis indicated that the amount of AlPcS2a in the
tumours was not significantly different between 2 and 48h after
administration (P¼0.62) and was about 400ngg
 1. Beyond 48h,
AlPcS2a was cleared from the tumour with an apparent elimination
rate constant of 0.0124h
 1 (C¼914e
 0.0124t). This constant is
based on the AlPcS2a concentration in the tumour (ngg
 1 tissue)
and is thus biased by the simultaneous growth of the tumour. The
tumour doubling time in these experiments was 14776h following
the regression line V¼85.5e
0.047t mm
3 (corr. coeff. R¼0.997). The
corrected elimination decay may thus be described as
A¼[914e
 0.0124t] [0.0855e
0.0047t]¼78e
 0.0077t, with the approx-
imation that 1g tissue equals 1ml. The corrected elimination rate
constant is 0.007770.0010h
 1, which indicates that the tumour
growth compensates for only 0.0047/0.0124¼38% of the tumour
concentration decay.
In vivo localisation of AlPcS2a in tumour-bearing mice
A major requirement for PDT and PCI is that the photosensitiser
should localise into the area to be treated. In addition, PCI requires
the photosensitiser to be located in the same endocytic vesicles of
parenchymal cells as the macromolecule of interest. Localisation in
the blood or the tissue stroma will reduce the synergism. Our
pharmacokinetic analysis indicated that AlPcS2a was essentially
eliminated from the serum within 24h, while the concentration in
tumour tissue was stable from 2 to 48h after administration. Thus,
the in vivo localisation of AlPcS2a was evaluated 2 and 48h after
administration by fluorescence microscopy. The cryosections
obtained 2h after sensitiser injection (Figure 2A) showed a
fluorescence pattern indicating AlPcS2a to be mainly in and near
vascular structures as well as in the stromal compartment of the
tumour, but with none in individual tumour cells. In contrast,
sections obtained after 48h (Figure 2B) showed a more diffuse
fluorescence concentrating in the tumour cells. Although limita-
tions in the resolution of cryosections do not allow precise
determination of intracellular localisation, the nuclei seem low in
AlPcS2a. Photosensitisers as used in PDT generally tend to
accumulate in neoplastic lesions (Dougherty et al, 1998). To verify
directly the accumulation of AlPcS2a in tumour tissue, whole-body
fluorescence imaging was used. Fluorescence emitted from tumour
tissue was detected 48h after photosensitiser injection (Figure 3A).
Dissection of the animal verified that the low signal detected
intraabdominally was from the liver (Figure 3B). The distribution
pattern of AlPcS2a fluorescence was similar after intravenous
injection (data not shown).
Quantification of gelonin distribution after intratumoral
injection
A prerequisite for photochemical activation of gelonin is its stable
presence in the tumour cells after intratumor injection. Gelonin
may be excreted by the highly vascularised sarcomas or degraded
by hydrolases. Figure 4 shows that undegraded gelonin is still in
the tumour 6h after injection, although reduced from the amount
injected. Traces of gelonin can be seen even 24h after injection. It
cannot be determined from these results whether the attenuation
of the gelonin content in the tumour tissue is due to elimination
into the blood or intratumoral degradation. No traces of
degradation products were observed on the Western blots.
PDT and PCI effect on tumour growth
The time for tumours to reach 1000mm
3 (our chosen end point, at
which time animals were killed by cervical dislocation) was the
same (3176 days) in all control groups (no treatment, gelonin and
light, AlPcS2a with gelonin in the absence of light (Figure 5, data
not shown)). Of 10 tumours treated with PDT, only one showed a
complete response and four showed a growth delay of approxi-
mately 17 days. The growth curves of the others were indis-
tinguishable from the controls. In animals treated with PCI, most
tumours disappeared by 15 days after the treatment. In total, 50%
of these animals (six of 12) remained tumour free although in the
other 50%, the tumours started to grow again by 20 days, taking
4379 days to reach 1000mm
3 (a delay of up to 30 days compared
with the controls (Po0.01) and up to 11 days compared with PDT-
treated animals (Po0.01)). There were no significant differences in
tumour volume at the time of light delivery between the complete
remission group and those that regrew later. All tumour-free
animals were followed for 110 days.
Histological examination of the central area of tumours 4 days
after treatment showed that in the PDT group, a mean of 25% of
the tumour was viable compared with 2.5% in the PCI group
(Po0.001) (Figure 6). Measured from the surface of the skin, the
PDT effect was typically 3–4mm deep compared with 6–7mm
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Figure 1 Time-dependent concentration of AlPcS2a in serum and
tumour after i.p. injection of 10mgkg
 1. Regression lines are used to
describe the decay of AlPcS2a levels from 48h after administration. Plots
are the mean values of 3–5 animals for each time point. Bars, s.d.
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s(and usually reaching the bottom of the tumour mass) for the PCI
group (Figure 6). Intratumour injection of gelonin or PBS with or
without light application induced a small amount of necrosis in the
centre of the tumour, presumably due to a local pressure effect.
However, this had no influence on the survival curve (Figure 5) or
the tumour growth (data not shown).
DISCUSSION
Photodynamic therapy is a versatile treatment modality for cancer
and is approved for use in the treatment of a variety of malignant
and premalignant conditions (Dougherty, 2002; Dolmans et al,
2003). However, one of its main limitations is the relatively poor
penetration of red light into tissue due to the absorption by natural
pigments such as haemoglobin and melanin. Photodynamic
therapy is therefore best suited to small and thin lesions
(Dougherty et al, 1998; Moan et al, 1998). However, PCI of gelonin
has been shown to reduce the fluence needed to obtain the same
cytotoxic effect as with PDT (Selbo et al, 2001; Dietze et al, 2003),
so increasing the depth of effect that can be achieved in solid
tumours. It was therefore of particular interest to study the
potential of PCI for the treatment of a solid tumour like the
sarcoma studied here. The structural properties of soft-tissue
2
 
h
AlPcS2a fluorescence HE staining
4
8
 
h
Figure 2 Distribution of AlPcS2a in tumours after i.p. injection of 10mgkg
 1 AlPcS2a. Upper photos (fluorescence and H&E staining): 6h after injection,
AlPcS2a is mainly in the tumour vasculature. Lower photos (fluorescence and H&E staining): 48h after injection, AlPcS2a is mainly intracellular.
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Figure 3 Macroscopic fluorescence 48h after i.p. injection of 10mgkg
 1 AlPcS2a. High fluorescence intensity is red and low intensity is blue. High intensity
was detected in the tumour region and in the liver.
Photodynamic destruction of a fibrosarcoma using PCI
A Dietze et al
2007
British Journal of Cancer (2005) 92(11), 2004–2009 & 2005 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
ssarcomas may influence the pharmacokinetics of the photosensi-
tiser as well as the possibility to activate the therapeutic potential
of macromolecules such as gelonin photochemically.
The serum pharmacokinetics of AlPcS2a in this study best fitted
a biexponential decay. The initial rapid elimination phase,
representing the distribution of the photosensitiser to the various
organs was followed by a second phase representing drug
elimination. The two half-lives are similar to those for the
clearance of m-THPC (Cramers et al, 2003; Jones et al, 2003). At
the start of the second phase (about 24h after administration), the
serum concentration is approximately 30-fold lower than in
tumour tissue, so from this time onwards, there is unlikely to be
a significant PDT effect on blood components under the
conditions required for tumour necrosis.
The tumour concentration of AlPcS2a also showed a two-phased
kinetic pattern, but with a stable concentration of about 400ngg
 1
tissue during the first 48h after administration followed by a single
exponential decay. In vitro studies indicate that photosensitisers
entering cells by endocytosis tend to be retained in these vesicles
for a long time (430h) as long as they are not released into the
cytosol by light activation (unpublished data). The tumour
clearance rate for AlPcS2a, corrected for tumour growth indicates
a half-life of 90h (56h uncorrected). This stable plateau of
photosensitiser concentration in tumour tissue for 1–2 days after
administration followed by clearance over several days has been
reported for several photosensitisers (Peng et al, 1991b). The half-
life for AlPcS2a in the tumour tissue is similar to or shorter than
that of mTHPC and does not indicate that AlPcS2a is retained in
the tumour tissue for a longer time than other photosensitisers
despite its expected retention in endocytic vesicles.
At 48h after administration, the whole-body fluorescence
images clearly showed a greater retention of AlPcS2a in the tumour
than in the surrounding tissue and the fluorescence microscopy
showed that the drug is localised in tumour cells. This would
appear to be the best time interval between drug administration
and light delivery. These results correlate well with other reports
and indicate that the structural properties of the sarcoma tissue do
not spoil the possibility of using PCI as a new treatment modality
(Peng and Moan, 1995; Selbo et al, 2001). The results are also in
accordance with previous studies, which indicated that AlPcS2a is
located in the cells of an experimental malignant melanoma rather
than in the interstitium (Peng et al, 1991a,b), and that the
compound has a high tumour to tissue ratio (Chan et al, 1990).
Our results showed an increased survival time in tumour-
bearing animals using the combination of the photoactivation of
AlPcS2a and gelonin (PCI) compared with PDT alone (light and
AlPcS2a) or gelonin alone. The 50% complete response rate
observed after PCI correlated with necrosis reaching a depth of
7mm and covering a mean of more than 97% of the cut surface of
tumours examined 4 days after light delivery. After PDT, the depth
of necrosis was no more than 3–4mm. This may indicate that
tumour eradication is related to a threshold number of tumour
cells surviving the treatment, and that this threshold may be
around 2.5%. In this study, the gelonin was given by direct i.t.
injection, so it is difficult to know exactly where it was located, but
it may also be possible to administer it systemically, when one
could be more confident that it reached all the cells in the target
area. Our findings also provide evidence that PCI using gelonin
effectively reduces the light fluence needed to obtain a cytotoxic
effect inside tumours compared with PDT alone (Berg et al, 1999;
Selbo et al, 2001). The fluence rate of 670nm light is reduced by
50% at a depth of 3mm (Moan et al, 1998).
This study was undertaken to investigate the possibility of using
PCI in the treatment of sarcoma patients before, during or after
surgery, particularly to reduce the incidence of local recurrence. At
present, 50% of patients die within 5 years due to local relapse or
metastases (Dirix and Van Oosterom, 1999). Chemotherapy and
radiation therapy often do not give satisfactory results and have
the disadvantages of troublesome side effects. Photochemical
internalisation has few side effects since the treatment effect is
localised to the illuminated area apart from skin photosensitivity
due to the photosensistiser, which is reasonably easy to control.
New developments in molecular biology have led to experimental
therapeutic approaches designed specifically to target changes in
malignant cells (Hunt and Feig, 1999). Previously we reported the
30 kDa  
A 
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MW 10min 6 h 24 h 48 h No gel  Empty Ctrl
Figure 4 (A) Western blot showing level of gelonin in tumour at times from 10min to 48h after direct i.t. injection of 50mg. The blot shows also an MW
standard of 30kDa as well as pure native gelonin as control (ctrl) and tumour extract from untreated tissue (no Gel). (B) The PVDF membrane was stained
with Ponceu S solution to verify even loading.
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Figure 5 Tumour growth after treatment (Kaplan–Meier plot). The five
groups treated were: group 1: PCI, group 2: PDT, group 3: no treatment,
group 4: AlPcS2aþgelonin (no light), group 5: geloninþlight (no AlPcS2a).
Animals were killed when the tumour volume reached 1000mm
3.
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spossibility of using PCI for the targeted delivery of macromole-
cules to cancer cells (Selbo et al, 2000; Prasmickaite et al, 2002;
Kloeckner et al, 2004). The combination of light-directed therapy
and molecular targeting which is possible using PCI could become
a powerful adjuvant treatment modality, which could meet the
needs of many patients with localised tumours that are difficult to
eradicate with current techniques.
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